Short Interest in Predictive Oncology Inc. (NASDAQ:POAI) Drops By 18.0%

Predictive Oncology Inc. (NASDAQ:POAI) saw a large drop in short interest in September. As of September 15th, there was short interest totalling 64,100 shares, a drop of 18.0% from the August 31st total of 78,200 shares. Approximately 1.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 2,700,000 shares, the short-interest ratio is presently 0.0 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright assumed coverage on shares of Predictive Oncology in a report on Monday, August 19th. They issued a “buy” rating and a $3.00 price objective for the company.

Predictive Oncology Price Performance

Predictive Oncology stock traded up $0.03 during mid-day trading on Friday, hitting $0.79. The company’s stock had a trading volume of 74,319 shares, compared to its average volume of 1,550,137. The business has a 50 day moving average price of $0.97 and a 200-day moving average price of $1.39. Predictive Oncology has a 12 month low of $0.75 and a 12 month high of $4.10. The stock has a market cap of $5.24 million, a price-to-earnings ratio of -0.22 and a beta of 1.13.

Predictive Oncology (NASDAQ:POAI) last issued its earnings results on Tuesday, August 13th. The medical instruments supplier reported ($0.68) earnings per share for the quarter. Predictive Oncology had a negative net margin of 802.69% and a negative return on equity of 200.06%. The company had revenue of $0.28 million for the quarter. On average, equities research analysts expect that Predictive Oncology will post -2.03 earnings per share for the current fiscal year.

About Predictive Oncology

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.